Needham & Company analyst Alan Carr reiterated a Hold rating on Arena Pharma (NASDAQ: ARNA) ahead of Q3 earnings.

This article: 173 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE